Cyramza

(Ramucirumab)

Cyramza

Drug updated on 11/10/2023

Dosage FormInjection (intravenous: 100 mg/10 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL))
Drug ClassHuman vascular endothelial growth factor 2 (VEGF2) antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
  • Indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
  • Indicated in combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza.
  • Indicated in combination with Folfiri, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
  • Indicated a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.

Product Monograph / Prescribing Information

Document TitleYearSource
Cyramza (ramucirumab) Prescribing Information.2022FDA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis2023Chinese medical journal
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review2023Frontiers in oncology
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis2023Therapeutic advances in chronic disease
Human medicine European public assessment report (EPAR): Cyramza2022EMA
Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.2022Future Oncology
Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis.2022JTO Clinical Research Reports
Impact of smoking status in combination treatment with EGFR tyrosine kinase inhibitors and anti-angiogenic agents in advanced non-small cell lung cancer harboring susceptible EGFR mutations: systematic review and meta-analysis.2022Journal of Clinical Medicine
Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: a network meta-analysis.2021PLoS One
Economic evaluation of monoclonal antibodies in metastatic colorectal cancer: a systematic review.2021Molecular Diagnostics & Therapy
Comparative efficacy and safety of anti-PD-1/PD-L1 immune checkpoint inhibitors for refractory or relapsed advanced non-small-cell lung cancer—a systematic review and network meta-analysis.2021Cancers
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a Systematic review and network meta-analysis.2020JAMA Oncology
Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review.2020Journal of the National Cancer Institute
Role of systemic treatment for advanced/metastatic gastric carcinoma in the third-line setting: a Bayesian network analysis.2020Frontiers in Oncology
Assessment report: Cyramza.2019EMA
Systemic therapy for previously treated advanced gastric cancer: a systematic review and network meta-analysis.2019Critical Reviews in Oncology / Hematology
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.2019BMC Cancer
Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials.2018BMC Research Notes
Ramucirumab safety in East Asian patients: a meta-analysis of six global, randomized, double-blind, placebo controlled, phase III clinical trials.2018Journal of Global Oncology

Clinical Practice Guidelines